These results demonstrate that RNAi silencing of AIF in breast adenocarcinoma cells leads to decreased AIF levels and decreased levels of nuclear AIF after treatment with a cytotoxic DNA-damaging agent. This evidence concerns the gene AIFM1 and breast adenocarcinoma.